Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

Regeneron's first-quarter results miss on lower Eylea demand Regeneron's first-quarter ... 2025 US FDA approves syringe version of Argenx's immune disorder drug The U.S. Food and Drug ...

A COUPLE who conceived their baby with a Calpol syringe have been left fuming after being told they can't both be on the birth certificate. Kerry and Anna welcomed daughter Ezmai in March ...

RICHMOND, Ind. — The Wayne County Board of Health this month recommended the renewal of the Syringe Services Program during its during its biannual review at a meeting on May 13. Dr. Jennifer Ba ...

Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the drug. The US regulator ...

The company has 11 FDA-approved drugs, including Dupixent and Eylea. 23andMe gene privacy question takes a turn in bankruptcy Why a big AI player wants a quarter-million bucks from 23andMe Why a ...

It also makes Eylea, which it developed with Bayer. Ahead of Monday's moves, Regeneron's stock has fallen 16.6% in 2025, while the S&P 500 SPX has risen 1.3%. Also read: Regeneron's earnings ...

A city litter-picking group said 105 discarded drug syringes were discovered by volunteers in a single day. Peterborough Litter Wombles and Cadent Gas organised a pick in and around the fields off ...